Kidney organoids and method for producing the same

Permeable porous wells and a novel protocol improve kidney organoid formation by enhancing nutrient exchange and oxygen control, resulting in more mature and functional nephron structures for kidney disease research and drug testing.

JP2024167448APending Publication Date: 2024-12-03POSTECH ACADEMY INDUSTRY FOUNDATION +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024160470
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-23
Filing Date
2024-09-17
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Conventional methods for forming kidney organoids using impermeable wells face challenges such as inadequate nutrient supply and metabolite removal, leading to reduced survival rates and immaturity, with limited vascularization and nephron-like structure immaturity.

Method used

The use of permeable porous wells and a new protocol involving hypoxic conditions, specific growth factors, and microwell culture to differentiate stem cells into metanephric mesenchymal cells, form cell aggregates, and differentiate into kidney organoids, utilizing GSK-3β and BMP4 inhibitors, activin A, FGF9, and FBS in controlled oxygen environments.

Benefits of technology

This approach enhances the differentiation success rate, forming kidney organoids with distinct tubular structures and improved nephron function, suitable for in vitro models of kidney diseases and drug evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167448000001_ABST
    Figure 2024167448000001_ABST
Patent Text Reader

Abstract

To provide kidney organoids and a method for producing the kidney organoids.SOLUTION: Disclosed is a method for producing kidney organoids including steps of: (1) differentiating stem cells into metanephric mesenchyme cells; (2) forming metanephric mesenchyme cell aggregates by culturing the metanephric mesenchyme cells; and (3) differentiating the metanephric mesenchyme cell aggregates into kidney organoids.SELECTED DRAWING: Figure 5
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to renal organoids and methods for producing the same, and more particularly, to a method for forming renal organoids with improved nephron structure by applying a permeable porous well and a new protocol. [Background technology]

[0002] Differentiation of pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), has enabled the generation of organoid models of various tissues, including the kidney.

[0003] Renal organoids are three-dimensional cell aggregates formed to mimic the developmental process of the kidney, and are composed of various kidney cells. By embodying a structure resembling the kidney, they have shown potential as an in vitro kidney model for evaluating the nephrotoxicity of drugs and for researching therapeutic agents for kidney diseases, etc. Therefore, many studies have been conducted to form renal organoids, and various methods for forming renal organoids have been proposed.

[0004] Generally, well-type platforms such as well plates and microwell arrays are used to form 3D kidney organoids, which can organize cells into 3D aggregates. However, conventional impermeable wells do not allow for smooth supply of nutrients and growth factors and removal of metabolites, which may reduce the viability of kidney organoids and cause immaturity.

[0005] Meanwhile, recently, with the progress in the stem cell field, several different protocols have been established to generate kidney organoids from human pluripotent stem cells (hPSCs). hPSC-derived kidney organoids have segmented structures including podocytes, proximal tubule epithelial cells, and distal tubule epithelial cells in a nephron-like arrangement. Comparative analysis of in vitro hPSC-kidney organoids and in vivo kidney tissues showed that kidney organoids recapitulate human kidney development. However, the limited vascularization and immaturity of the nephron-like structures are still challenges to be overcome. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Korea 10-2020-0010279 Summary of the Invention [Problem to be solved by the invention]

[0007] Therefore, one aspect of the present invention is to provide a method for producing kidney organoids with improved nephron structure by applying permeable porous wells and new protocols. [Means for solving the problem]

[0008] According to one aspect of the present invention, there is provided a method for producing kidney organoids, comprising a first step of differentiating stem cells into metanephric mesenchymal cells, a second step of culturing the metanephric mesenchymal cells to form cell aggregates, and a third step of differentiating the metanephric mesenchymal cell aggregates into kidney organoids.

[0009] Furthermore, in the method for producing kidney organoids according to the present invention, the first step of differentiating into metanephric mesenchymal cells may be carried out in a hypoxic environment with an oxygen concentration of less than 10%.

[0010] Furthermore, in the method for producing renal organoids according to the present invention, the first step of differentiating into metanephric mesenchymal cells may include a step of culturing in at least one of the following media: i) a medium containing a GSK-3β inhibitor and a BMP4 inhibitor, ii) a medium containing activin A, iii) a medium containing FGF9, and a medium containing a mixture of at least two of these, and may be carried out for 8 to 9 days.

[0011] Furthermore, in the method for producing renal organoids according to the present invention, the second step of forming the cell aggregates may be carried out for 2 to 3 days in a medium containing a GSK-3β inhibitor and FGF9.

[0012] Furthermore, in the method for producing a renal organoid according to the present invention, the third step of differentiating into the renal organoid may be carried out for 7 to 100 days in a medium containing FBS.

[0013] Furthermore, in the method for producing renal organoids according to the present invention, the second and third steps may be carried out in a microwell.

[0014] Furthermore, in the method for producing renal organoids according to the present invention, the microwell may include one or more recesses.

[0015] Furthermore, in the method for producing renal organoids according to the present invention, the microwell may be a porous microwell.

[0016] Furthermore, the renal organoid according to the present invention is a renal organoid differentiated from a metanephric mesenchymal cell aggregate formed under hypoxic conditions, and is characterized in that the expression level of at least one of mRNA corresponding to the proximal tubule, mRNA corresponding to Henle's loop, and mRNA corresponding to the distal tubule is relatively high compared to a renal organoid differentiated from a metanephric mesenchymal cell aggregate formed under normoxic conditions, and the hypoxic condition may be an oxygen concentration of more than 1% to less than 10%, and the normoxic condition may be an oxygen concentration of 10% or more. Effect of the Invention

[0017] According to the present invention, the application of a new protocol improves the success rate of differentiation, allows the formation of clearer tubular structures, and furthermore, by utilizing permeable wells, kidney organoids that express improved nephron functions can be formed. Therefore, when using kidney organoids obtained by the present invention, in fields where in vitro kidney models are used, such as research on kidney-related diseases and evaluation of nephrotoxic drugs, phenomena such as actual in vivo kidney diseases and drug absorption can be mimicked in vitro, and thus the kidney organoids can be widely used in the pharmaceutical and tissue engineering fields. [Brief description of the drawings]

[0018] [Figure 1] 1A-1C show exemplary steps for fabricating a permeable well applicable to the present invention and the fabricated well. [Diagram 2] FIG. 2 shows a cross section of a permeable well applicable to the present invention. [Diagram 3] FIG. 1 shows kidney organoids formed on permeable wells obtained by an embodiment of the present invention. [Figure 4] FIG. 1 shows the results of immunofluorescence staining of kidney organoids formed in impermeable well arrays compared to immunofluorescence staining of kidney organoids formed in permeable well arrays. [Diagram 5]FIG. 1 shows the results of comparing the maturity of kidney organoids formed in impermeable well arrays with that of kidney organoids formed in permeable well arrays. [Figure 6] FIG. 1 shows the difference depending on the oxygen conditions in the first step. [Figure 7] Figure 7(a) is a graph showing the results of reverse transcription-polymerase chain reaction analysis of the expression level of Brachyury (T), a marker for the late primitive streak, to confirm differences due to oxygen conditions in the first step, and Figure 7(b) is a graph showing the results of immunofluorescent staining analysis of kidney organoids formed on day 21 of differentiation, showing that nephron structure was observed more clearly under low oxygen conditions (5%). [Figure 8] FIG. 1 shows the results of observing tubular or connecting structures within renal organoids differentiated under each oxygen condition. [Figure 9] FIG. 1 shows the results of observing tubular or connecting structures within renal organoids differentiated under each oxygen condition. [Figure 10] This figure compares the cell surfaces of renal organoids differentiated under each oxygen condition. [Figure 11] FIG. 1 shows the results of comparative observation of the shape and differentiation state of ureteric buds (UB). [Figure 12] FIG. 13 shows the development of nephron structure depending on the concentration of FGF9 in the third step. [Figure 13] FIG. 13 shows the results of an analysis by immunofluorescence staining of the degree of differentiation depending on whether or not FBS is included in the third step. [Figure 14] FIG. 1 shows the results of evaluating drug toxicity of renal organoids formed on permeable wells according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings. However, the present invention can be modified in various ways, and the scope of the present invention is not limited to the following embodiments.

[0020] The method for producing renal organoids of the present invention includes a first step of differentiating stem cells into metanephric mesenchyme cells, a second step of culturing the metanephric mesenchyme cells to form cell aggregates, and a third step of differentiating the metanephric mesenchyme cell aggregates into renal organoids.

[0021] The stem cells that can be used in the present invention may be at least one of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), for example, induced pluripotent stem cells (iPSCs).

[0022] The basal medium that can be used in the present invention is a basal medium used for culturing animal cells, and includes, for example, IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM), alpha-minimum essential medium (αMEM), Dulbecco's Modified Eagle's Medium (DMEM), Ham's F12 medium, Roswell Park Memorial Institute (RPMI) 1640 medium, Advanced RPMI 1640 medium, Fischer's medium, McCoy's 5A medium, Basal medium Eagle's (BME), MCDB media, and mixtures thereof. For example, Advanced RPMI 1640 has a lower FBS content than RPMI 1640, and therefore is preferable because it allows experiments to be performed with higher reproducibility without changes in cell growth rate or cell morphology and function.

[0023] If necessary, the medium may contain one or more serum substitutes such as albumin, transferrin, KnockOut Serum Replacement (KSR: KnockOut Serum Replacement) (serum replacement for ES cell culture) (Invitrogen), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, etc., or may contain one or more substances such as lipids, amino acids, L-glutamine, GlutaMAX (Invitrogen), non-essential amino acids (NEAA), vitamins, growth factors, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, and the like. Media previously optimized for stem cell culture, such as ReproFF2 (ReproCell) and StemFit Basic medium (Ajinomoto Co., Inc.), may also be used.

[0024] On the other hand, the first step of differentiation into metanephric mesenchymal cells is preferably performed under a low oxygen atmosphere with an oxygen concentration of more than 1% to less than 10%, for example, an oxygen partial pressure of more than 1% to 5% or less. When the oxygen concentration in the first step is 10% or more, there is a problem in the stable induction of a dome-like shape that should appear preferably on about the 4th day in the first step, which is the initial step of differentiation. In addition, when the oxygen concentration in the first step is 1%, the kidney organoids formed as a result of differentiation up to the 9th day were relatively small, making it difficult to observe the nephron structure, and the number of organoids formed was also significantly reduced compared to differentiation under conditions of an oxygen concentration of 5%, so it was confirmed that there is a problem in that differentiation is unstable under conditions of an oxygen concentration of 1% or less.

[0025] In the early stage of the development process of an actual human embryo, vascularization does not occur, and development proceeds in a hypoxic environment. Based on the fact that kidney development under such hypoxic conditions improves tubule formation through activation of HIF, a hypoxia-inducing factor, in the present invention, the atmosphere in the first step, which is the initial step, during kidney organoid differentiation is set to a hypoxic condition, which is an embryonic development environment. Meanwhile, in the second and third steps, differentiation is performed under normal oxygen partial pressure. Thus, kidney organoids differentiated by the new protocol in which hypoxic conditions are introduced in the first step can exhibit clear tubule structures with a high reproducibility after the completion of the third step, for example, on the 21st day, compared to kidney organoids differentiated under conditions in which hypoxic conditions are not introduced.

[0026] On the other hand, the first step of differentiating into metanephric mesenchymal cells may include culturing in at least one of the following media: i) a medium containing a GSK-3β inhibitor and a BMP4 inhibitor, ii) a medium containing activin A, iii) a medium containing FGF9, and a medium containing a mixture of at least two of these, and may be carried out for 8 to 10 days.

[0027] For example, the first step of differentiating into metanephric mesenchymal cells preferably includes the steps of sequentially culturing in i) a medium containing a GSK-3β inhibitor and a BMP4 inhibitor, ii) a medium containing activin A, and iii) a medium containing FGF9 for 1 to 4 days per medium. For example, the cells may be sequentially cultured in i) a medium containing a GSK-3β inhibitor and a BMP4 inhibitor for about 4 days, ii) a medium containing activin A for about 3 days, and iii) a medium containing FGF9 for about 2 days.

[0028] Examples of the BMP4 inhibitor include protein inhibitors such as Chordind, Noggin, and Follistatin, Dorsomorphin (6-[4-(2-piperidin-1-yl-ethoxy)phenyl]-3-pyridin-4-yl-pyrazolo[1,5]-a]pyrimidine), LDN193189 (4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline), Gremlin (Grem1), sclerostin, and twisted gastrulation (Tsg) protein. A preferred BMP4 inhibitor is NOGGIN, and the concentration may be, for example, 1 to 100 ng / ml, preferably 5 to 20 ng / ml.

[0029] Examples of the GSK-3β inhibitor include CHIR and CHIR99021. The concentration of the GSK-3β inhibitor can be appropriately selected by those skilled in the art depending on the GSK-3β inhibitor used, and is, for example, 0.01 to 100 μM, preferably 0.1 to 10 μM.

[0030] The second step of forming the cell aggregates is preferably carried out for 2 to 3 days in a medium containing a GSK-3β inhibitor and FGF9.

[0031] On the other hand, the FGF9 concentration of the culture medium used in the first and second steps is 5 ng / ml or more and less than 25 ng / ml. If the FGF9 concentration is less than 5 ng / ml, there are problems with the development and maintenance of nephron stem cells, and if it is 25 ng / ml or more, there is a problem that the efficiency of differentiation into renal organoids is unstable.

[0032] The third step of differentiating into renal organoids is preferably performed in a medium containing FBS for 7 to 100 days, for example, 10 to 50 days, or 15 to 30 days, for example, 16 to 21 days. For example, the third step of differentiating into renal organoids is performed in a medium containing 0.5 to 5% by volume of FBS with respect to the total volume of the medium composition for 7 to 100 days. If the FBS concentration is less than 0.5% by volume, there is a problem in observing the nephron structure of the formed renal organoid, and if it exceeds 5% by volume, there is a problem in differentiating into renal organoids because it affects the cell growth rate and gene and protein expression, and the phenotype of the cell may change.

[0033] As mentioned above, when FBS components are included, by supplying the growth factors, ECM molecules, hormones, etc. contained in the FBS to the three-dimensional kidney organoids, differentiation can be performed normally while maintaining cell viability until differentiation is complete.

[0034] On the other hand, the third step of differentiating into renal organoids includes a step of culturing for 2 to 5 days with 25 to 50 ng / ml, for example, 25 to 40 ng / ml of FGF9, and is preferably performed with a high concentration of FGF9, unlike the low concentration of FGF9 in the first and second steps. If the FGF9 concentration in the third step is less than 25 ng / ml, there is a problem in that the renal organoids have a developed tubular structure, and if it exceeds 50 ng / ml, it affects the cell proliferation rate and there is a problem in stably differentiating the renal organoids.

[0035] On the other hand, the step of culturing for 2 to 5 days in a medium further containing 25 to 50 ng / ml of FGF9 may be included at the start or early stage of the third step, and preferably, the culture is performed using a medium further containing 25 to 50 ng / ml of FGF9 for 2 to 5 days from the start of the third step.

[0036] When differentiating into cell aggregates in the second step, growth factors are not sufficiently delivered to the cell aggregates, so in the third step, the concentration of FGF9, which is necessary for the growth and maintenance of nephron stem cells, can be increased to 25-50 ng / ml to better improve differentiation into tubular structures.

[0037] Meanwhile, in the present invention, the second and third steps are preferably performed in a microwell, and in this case, the microwell may include one or more recesses, and the one or more recesses are preferably formed in the lower part of the microwell. Meanwhile, the microwell is preferably a porous microwell, and the porous microwell may be formed of a porous membrane. For example, the technology relating to a porous microwell described in Korean Patent Registration No. 10-2224065B1 may be adopted.

[0038] When renal organoids are differentiated using the protocol of the present invention as described above, the differentiation success rate is uniform and stable, and reproducible renal organoids can be formed.

[0039] The protocol provided by the method for producing kidney organoids of the present invention improves the success rate of differentiation and enables smooth formation of renal tubule structures.

[0040] The present invention will be described in more detail with reference to the following specific examples. The following examples are merely illustrative to aid in understanding the present invention, and the scope of the present invention is not limited thereto.

[0041] Working Example 1. Preparation of Kidney Organoids Example 1 Induced pluripotent stem cells (iPSCs) (IMR90-4, WiCell or WTC-11, CORIELL INSTITUTE) were seeded at a concentration of 25,000 to 30,000 cells / well on a 24-well plate coated with 1% Geltrex, using mTeSRTM1 medium containing 10 μM Y-27632. After one day, the medium was replaced with fresh mTeSRTM1 medium, and it was confirmed that the stem cells (iPSCs) formed colonies (cell groups).

[0042] When the stem cell (iPSC) colonies filled the wells by about 35-40%, the differentiation step was started in a differentiation medium with an oxygen partial pressure of 5% (D0). At this time, a mixed medium of Advanced RPMI 1640 containing CHIR 10 μM, Glutamax 100× (i.e., 1% by volume relative to the total volume of the total medium composition), and Noggin 10 ng / ml (a medium with a lower FBS content than RPMI 1640) was used as the differentiation medium, and the differentiation was performed in a low-oxygen environment (5% O2). On the second day (D2), the differentiation medium was replaced with a new one, and on the fourth day (D4), when the morphology of the cells became dome-like, the cells were treated with Activin A medium. At this time, a mixed medium of Advanced RPMI 1640 containing Activin A 10 ng / ml and Glutamax 100× (1% by volume relative to the total volume of the total medium composition) was used as the Activin A medium. On day 7 (D7), the cells were treated with low-concentration FGF9 medium. The low-concentration FGF9 medium used was a mixed medium of Advanced RPMI 1640 containing 10 ng / ml FGF9 and Glutamax 100x (1% by volume relative to the total volume of the entire medium composition).

[0043] The permeable well used in this case can be prepared as shown in FIG. 1. First, as shown in FIG. 1(a), a permeable membrane is prepared by electrospinning using a solution of 5 to 25% concentration obtained by mixing polycaprolactone and Pluronic F108 in a 5:5 ratio in a hexafluoro-2-propanol solution. Then, as shown in FIG. 1(b), a permeable well can be produced through a thermoforming process using a negative mold and a positive mold. It can be seen that the permeable well produced in this way has a porous structure (FIG. 1(c)). A cross section of the permeable well used in the present invention is shown in FIG. 2.

[0044] On the 9th day (D9), metanephric mesenchyme cells differentiated in a well plate were separated by treating with Accutase, and then seeded in a permeable well at 20,000 cells / well based on 800 μM well. The medium used was a mixed medium of Advanced RPMI 1640 and Glutamax 100× (1% by volume relative to the total volume of the entire medium composition) containing 3 μM CHIR and 10 ng / ml FGF9, and the cells were cultured at an oxygen partial pressure of 21% from the 9th day to form cell aggregates.

[0045] On day 11 (D11), the medium was replaced with a high-concentration FGF9 medium, which was a mixed medium of 30 ng / ml FGF9, Advanced RPMI 1640, and Glutamax 100x (1% by volume relative to the total volume of the entire medium composition), and the cells were cultured at an oxygen partial pressure of 21% to differentiate into the renal vesicle stage.

[0046] On day 14 (D14), the cells were cultured for up to day 21 using a mixed medium of Advanced RPMI 1640 containing 1.5% by volume of FBS relative to the total medium volume and Glutamax 100x (1% by volume relative to the total volume of the total medium composition) as a basic differentiation medium. As a result, kidney organoids formed on the permeable wells were confirmed as shown in FIG. 3.

[0047] Comparative Example 1 Renal organoids were produced by the same procedure as in Example 1, except that Aggrewell™ was used as an impermeable well instead of a permeable well.

[0048] 2. Confirmation of differences in kidney organoids by well type (1) Confirmation of uniformity of differentiation On differentiation day 21 (D21), the differentiated kidney organoids were washed with DPBS (Dulbecco's PBS) for 5 minutes, and then treated with 4% PFA (volume) for 2 hours at room temperature to fix the kidney organoids. After 2 hours, the organoids were washed 3 times for 10 minutes each with DPBS, and blocked with 0.3% Triton X-100 and 5% donkey serum (volume) for the total buffer solution volume at room temperature. After 2 hours of treatment, the primary antibody was diluted in a buffer solution containing 0.3% Triton X-100 and 0.5% bovine serum albumin (BSA) (0.5% BSA (mass / volume)) for the total buffer solution volume, and treated at 4°C for 5 days. The organoids were washed three times for 10 minutes at room temperature with PBST containing 0.3% by volume of Triton X-100 relative to the total buffer solution volume, and the secondary antibody was diluted with a buffer containing 0.3% by volume of Triton X-100 and 0.5% by volume of bovine serum albumin (BSA) relative to the total buffer solution volume, and treated overnight at 4 ° C. The next day, the organoids were washed three times for 20 minutes at room temperature with PBST containing 0.3% by volume of Triton X-100 relative to the total buffer solution volume, and DAPI (4',6-diamidino-2-phenylindole) was diluted to a concentration of 1 μg / ml with DPBS, and treated overnight at 4 ° C., and then washed three times for 10 minutes with DPBS. By this procedure, immunofluorescence staining experiments were performed on the kidney organoids prepared in Example 1 and Comparative Example 1 above.

[0049] As can be seen from the results of comparing the immunofluorescent staining of kidney organoids formed in an impermeable well array and that formed in a permeable well array shown in (a) of FIG. 4, when comparing PODXL (podocyte), LTL (proximal tubule epithelial cell), and ECAD (distal tubule epithelial cell) markers present in the kidney nephron, it was confirmed that the kidney organoids formed in the permeable well of Example 1 according to the present invention were uniformly well differentiated, whereas the kidney organoids formed in the impermeable well array of Comparative Example 1 showed reduced uniformity. In addition, when the uniformity was quantitatively examined, as shown in (b) of FIG. 4, it was confirmed that the diameter of the kidney organoids formed in the impermeable well array was 100 to 400 μm, and the diameter of the kidney organoids formed in the permeable well array was 200 to 350 μm. In other words, renal organoids formed in the impermeable well array differentiated heterogeneously into renal organoids with different diameter values, whereas renal organoids formed in the permeable well array differentiated uniformly into renal organoids with relatively similar diameter values.

[0050] (2) Confirmation of kidney organoid maturity Reverse transcription quantitative polymerase chain reaction (RT-qPCR) The maturity of the differentiated kidney organoids was analyzed by quantifying the markers expressed in the kidney organoids using induced pluripotent stem cells (iPSCs) as a control group. In the experimental conditions, after treatment at 95°C for 1 minute, 15 seconds at 95°C, 15 seconds at 56°C or 62.7°C, and 45 seconds at 72°C were repeated 40 times. By this procedure, an experiment was conducted to confirm the maturity of the kidney organoids produced in the above Example 1 and Comparative Example 1.

[0051] As a result, as shown in Figure 5, when comparing the PODXL (podocyte), LTL (proximal tubular epithelial cell), and ECAD (distal tubular epithelial cell) markers present in the kidney nephron, it was confirmed that the renal organoids formed in the permeable well array of Example 1 according to the present invention showed improved results in all markers compared to the renal organoids formed in the impermeable well array of Comparative Example 1. Specifically, compared with the renal organoids formed in the impermeable well, the renal organoids formed in the permeable well showed higher expression levels of mRNA corresponding to PODXL (podocyte; podocyte), mRNA corresponding to LTL (proximal tubular cell), and mRNA corresponding to ECAD (distal tubular cell), all within a range of more than 1-fold and less than 2-fold.

[0052] 3. Confirmation of differences in kidney organoids by protocol (1) Differences in oxygen concentration in the first step of cell differentiation Renal organoids were produced using the same procedure as in Example 1, but when differentiation was performed in the first step under an oxygen concentration of 21% rather than under hypoxic conditions, the cell morphology was not densely packed into a dome-like shape even on the fourth day of differentiation, as shown in Figure 6 (right photo). However, when differentiation was performed under 5% hypoxic conditions, a dome-like shape was observed after three days and maintained until the fourth day, and it was confirmed that a stable dome-like shape was observed in each batch on the fourth day of differentiation (left photo).

[0053] To confirm this more clearly, the expression level of Brachyury (T), a marker for the late primitive streak, was analyzed by reverse transcription polymerase chain reaction. As a result, as shown in Figure 7 (a), it was confirmed that the expression level of Brachyury (T), a marker for the late primitive streak, was further increased in renal organoids differentiated in a 5% hypoxic environment compared to a 21% oxygen environment.

[0054] Furthermore, immunofluorescence staining analysis on day 21 of differentiation showed that nephron structure was more clearly observed under 5% hypoxia (Figure 7(b)).

[0055] In addition, a significant difference was confirmed when kidney organoids differentiated under 5% hypoxic conditions until day 9 were compared with kidney organoids differentiated under normoxic conditions (e.g., 21% oxygen environment) until day 9 by immunofluorescence staining experiments. Specifically, as shown in (a) of Figure 8, it was confirmed that the tubular structures stained with the proximal tubule (LTL) marker and the distal tubule (ECAD) marker observed in kidney organoids differentiated under hypoxic conditions were longer than those observed in kidney organoids differentiated under normoxic conditions. In addition, a quantitative analysis of this confirmed that the "staining rate of tubule markers per organoid" of organoids differentiated under hypoxic conditions was higher than that of organoids differentiated under normoxic conditions. Figure 8(b) is a graph comparing the mRNA expression levels of each tubule marker, and it was confirmed that the expression levels of mRNAs (ABCB1, AQP1, SLC34A1) corresponding to proximal tubules, mRNA (UMOD) corresponding to Henle's loop, and mRNA (ECAD) corresponding to distal tubules in organoids differentiated under hypoxic conditions were relatively higher than those in organoids differentiated under normoxic conditions. More precisely, in the case of organoids differentiated under hypoxic conditions, the expression levels of ABCB1 mRNA were more than 3 times higher, AQP1 mRNA was more than 2 times higher, SLC34A1 mRNA was more than 2 times higher, UMOD mRNA was more than 1.5 times higher, and ECAD mRNA was more than 2 times higher than those in organoids differentiated under normoxic conditions.

[0056] On the other hand, kidney organoids formed under 5% hypoxic conditions not only had longer tubular structures than kidney organoids formed under normoxic conditions as described above, but also appeared to connect adjacent organoids due to the longer tubular structures. It is known that the human nephron structure is such that nephrons are connected to each other by renal tubules deep in the cortex. The observation that adjacent organoids are connected to each other by long tubular structures under hypoxic conditions suggests that kidney organoids formed under hypoxic conditions are similar in structure to actual human nephrons.

[0057] Figure 9 shows another result of comparative observation of the connection structure in kidney organoids formed under normoxic conditions (oxygen environment 21%) and hypoxic conditions (oxygen environment 5%). Referring to (a) of Figure 9, it can be seen that under normoxic conditions, no special connection structure is seen between adjacent organoids in the photograph, whereas under hypoxic conditions, tubular structures are formed between adjacent organoids. In addition, (b) of Figure 9 shows the staining results of ECAD marker stained in both distal tubules and collecting ducts, and CALB1 marker stained in collecting ducts. Unlike the normoxic condition on the left, in the hypoxic environment on the right, the CALB1 marker is clearly visible in the long tubular structure connecting adjacent organoids, indicating that collecting ducts are structurally formed between adjacent organoids in organoids differentiated under hypoxic conditions. For reference, the left photograph of (b) is shown at a scale of 1:50 μm, and the right photograph is shown at a scale of 1:100 μm. In addition, (c) of FIG. 9 is a graph showing a relative comparison of the expression levels of four types of genes, including the three types of cells that compose the collecting duct and their markers, principal cells (AQP2, AQP4), type alpha intercalated cells (SLC4A1), and type beta intercalacted cells (SLC26A4). In the case of organoids differentiated under hypoxic conditions, the expression levels of AQP2 mRNA were more than twice as high, AQP4 mRNA was more than twice as high, SLC4A1 mRNA was more than 1.5 times as high, and SLC26A4 mRNA was more than twice as high, compared to those differentiated under normoxic conditions. On the other hand, as a result of observing kidney organoids differentiated under hypoxic conditions on the 21st day, as shown in (d), it was confirmed that the expression level of CALB1 gene, a principal cell marker of the collecting duct, was more than 15 times higher than that of kidney organoids differentiated under normoxic conditions.

[0058] FIG. 10(a) shows a comparison of the cell surfaces of renal organoids differentiated under normoxic conditions (oxygen concentration 21%) and hypoxic conditions (oxygen concentration 5%) using SEM images. It is known that in human kidneys, proximal tubular epithelial cells have one long primary cilium and microvilli present around it, while distal tubular epithelial cells have only one long primary cilium without microvilli. It is also known that the primary cilium plays a role in maintaining the structure and function of the nephron in the kidney. Referring to FIG. 10(a), it was confirmed from the photographic image that compared with organoids differentiated under normoxic conditions, organoids differentiated under hypoxic conditions have microvilli of proximal tubular epithelial cells formed at a higher density, and the primary cilia of proximal tubular epithelial cells and distal tubular epithelial cells are also formed longer, which is similar to the length of actual human cilia. Figure 10(b) shows a comparison of gene expression levels of the protein ANO1, which is expressed in primary cilia and affects cilia development. It was observed that the ANO1 mRNA expression level under hypoxic conditions was more than 1.5 times higher than that under normal oxygen conditions. This suggests that cilia are longer under hypoxic conditions.

[0059] Figure 11 shows the results of comparative observation of the shape and differentiation of ureteric bud (UB), which is a collecting duct stem cell. The time when nephron stem cells are formed by the formation of collecting ducts is the 9th day. At this time, the formation and differentiation of ureteric bud (UB) under normoxic conditions (oxygen concentration 21%) and hypoxic conditions (oxygen concentration 5%) were compared, and it was confirmed that the patterns were significantly different under both conditions. Referring to (a) of Figure 11, it can be seen that CALB1, which is used as a collecting duct marker and UB marker, is expressed under both conditions, and its expression pattern is that it does not form a specific structure under normoxic conditions, whereas under hypoxic conditions, CALB1 is structurally expressed along the periphery of renal vesicles where SIX2 is expressed. In addition, as a result of staining and comparison of hypoxia-inducible factor (HIF1A), which is known to accumulate under hypoxic environments, it was confirmed that the expression level under hypoxic conditions was significantly higher than that under normoxic conditions, and it was inferred that it accumulated at the expression site of CALB1 and affected the development of collecting ducts. On the other hand, at the genetic level, a comparison of the mRNA expression levels between MM (Metanephric mesenchyme) cells and UB cells revealed that under hypoxic conditions, the MM marker SIX2 was relatively decreased compared to normoxic conditions, whereas the UB marker CALB1 was increased by more than 1.5-fold compared to normoxic conditions. This indicates that collecting ducts are formed under hypoxic conditions as a result of the development of UB cells during differentiation.

[0060] (2) Differences in FGF9 concentration in the third step of differentiation into organoids Renal organoids were produced using the same procedure as in Example 1. However, in the third step, when treated with media containing FGF9 at concentrations of 10 μg / ml or 20 μg / ml, a problem occurred in which the organoids did not have a stable nephron structure in any of the media.

[0061] On the other hand, when renal organoids were differentiated in a medium mixed at a concentration of 30 ng / ml as in Example 1, it was observed that the cells developed more stably into nephron structures, and in particular, differentiated clearly into tubular structures, and it was confirmed that treatment with a higher concentration of FGF9 of 30 ng / ml was preferable in the third differentiation step. Figure 12 shows the development into nephron structures depending on the FGF9 concentration in the third step.

[0062] (3) Differences in the presence or absence of FBS in the third step of differentiation into organoids The degree of differentiation into organoids in the third step, with or without FBS, was analyzed by immunofluorescence staining, and the results are shown in Figure 13. As shown in Figure 13, in kidney organoids differentiated in a medium composition without FBS, no nephron structure was observed inside, but in kidney organoids differentiated in a medium composition containing 1.5% FBS by volume of the total medium composition, a structure similar to a nephron was confirmed to exist inside.

[0063] 4. Assessing Drug Toxicity in Renal Organoids Advanced RPMI 1640 was treated with tacrolimus at 0, 30, and 60 μM at 37° C. for 24 hours, and after 24 hours, the cells were washed three times with DPBS, and then live cells and tetrapods were stained with calcein-AM and ethidium homodimer-1, respectively. By this procedure, the drug toxicity of the kidney organoids obtained in Example 1 was evaluated.

[0064] As a result, as shown in Figure 14, when cells were treated with various concentrations of tacrolimus (FK506), which is known to be nephrotoxic, it was observed that the higher the concentration, the more cells died, confirming that renal organoids according to the present invention were produced.

[0065] Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and it will be obvious to those having ordinary skill in the art that various modifications and variations are possible without departing from the technical idea of ​​the present invention described in the claims.

Claims

1. A first step of differentiating stem cells into metanephric mesenchyme cells; a second step of culturing the metanephric mesenchymal cells to form cell aggregates; and a third step of differentiating the metanephric mesenchymal cell aggregates into kidney organoids. A method for producing kidney organoids, comprising the steps of:

2. The first step of differentiation into metanephric mesenchymal cells is carried out in a hypoxic environment with an oxygen concentration of less than 10%. A method for producing renal organoids as described in claim 1.

3. The first step of differentiating the cells into metanephric mesenchymal cells includes culturing the cells in at least one of the following media: i) a medium containing a GSK-3β inhibitor and a BMP4 inhibitor; ii) a medium containing activin A; iii) a medium containing FGF9; and a medium containing a mixture of at least two of these media; and the first step is performed for 8 to 9 days. A method for producing renal organoids as described in claim 1.

4. The second step of forming the cell aggregates is carried out for 2-3 days in a medium containing a GSK-3β inhibitor and FGF9. A method for producing renal organoids as described in claim 1.

5. The third step of differentiation into kidney organoids is carried out in a medium containing FBS for 7 to 100 days. A method for producing renal organoids as described in claim 1.

6. The third step of differentiating into renal organoids includes culturing for 2 to 5 days in the presence of 25 to 50 ng / ml FGF9. A method for producing renal organoids as described in claim 1.

7. The second and third steps are carried out in microwells. A method for producing renal organoids as described in claim 1.

8. The microwell comprises one or more recesses. A method for producing renal organoids as described in claim 7.

9. The microwell is a porous microwell. A method for producing renal organoids as described in claim 8.

10. A kidney organoid differentiated from metanephric mesenchymal cell aggregates formed under hypoxic conditions, The kidney organoids are The renal organoids are characterized by having a relatively high expression level of at least one of mRNA corresponding to proximal tubules, mRNA corresponding to Henle's loop, and mRNA corresponding to distal tubules, as compared to renal organoids differentiated from metanephric mesenchymal cell aggregates formed under normal oxygen conditions; The low oxygen condition is an oxygen concentration of more than 1% to less than 10%, The normoxic condition is an oxygen concentration of 10% or more. A kidney organoid characterized by:

Citation Information

Patent Citations

  • Method for inducing differentiation from intermediate mesoderm cells into renal progenitor cells and method for inducing differentiation from pluripotent stem cells into renal progenitor cells

    KR1020200010279A